Maturation of human cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) on polycaprolactone and polyurethane nanofibrous mats.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Myocytes, Cardiac*/cytology ; Myocytes, Cardiac*/metabolism ; Induced Pluripotent Stem Cells*/cytology ; Induced Pluripotent Stem Cells*/metabolism ; Polyurethanes*/chemistry ; Polyesters*/chemistry ; Nanofibers*/chemistry ; Cell Differentiation*/drug effects ; Tissue Scaffolds*/chemistry; Humans ; Tissue Engineering/methods ; Cells, Cultured

Investigating the potential of human cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) in in vitro heart models is essential to develop cardiac regenerative medicine. iPSC-CMs are immature with a fetal-like phenotype relative to cardiomyocytes in vivo. Literature indicates methods for enhancing the structural maturity of iPSC-CMs. Among these strategies, nanofibrous scaffolds offer more accurate mimicry of the functioning of cardiac tissue structures in the human body. However, further research is needed on the use of nanofibrous mats to understand their effects on iPSC-CMs. Our research aimed to evaluate the suitability of poly(ε-caprolactone) (PCL) and polyurethane (PU) nanofibrous mats with different elasticities as materials for the maturation of iPSC-CMs. Analysis of cell morphology and orientation and the expression levels of selected genes and proteins were performed to determine the effect of the type of nanofibrous mats on the maturation of iPSC-CMs after long-term (10-day) culture. Understanding the impact of 3D structural properties in in vitro cardiac models on induced pluripotent stem cell-derived cardiomyocyte maturation is crucial for advancing cardiac tissue engineering and regenerative medicine because it can help optimize conditions for obtaining more mature and functional human cardiomyocytes.
(© 2024. The Author(s).)

Stem Cell Res. 2021 Apr;52:102225. (PMID: 33588215)
Nat Rev Cardiol. 2020 Jun;17(6):341-359. (PMID: 32015528)
Int J Nanomedicine. 2020 Jun 18;15:4205-4224. (PMID: 32606673)
Biomed Mater. 2024 Feb 12;19(2):. (PMID: 38290152)
J Biomed Mater Res A. 2022 Dec;110(12):1932-1943. (PMID: 35851742)
Nanomaterials (Basel). 2020 Dec 24;11(1):. (PMID: 33374248)
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:305-316. (PMID: 28415467)
PLoS One. 2015 May 19;10(5):e0126338. (PMID: 25993466)
J Biomed Mater Res B Appl Biomater. 2011 Aug;98(2):379-86. (PMID: 21681953)
Int J Mol Sci. 2022 Jan 04;23(1):. (PMID: 35008953)
Front Chem. 2022 Jan 19;9:809676. (PMID: 35127651)
Stem Cell Res Ther. 2022 Jun 3;13(1):232. (PMID: 35659761)
Biosci Rep. 2021 Jun 25;41(6):. (PMID: 33057659)
Methods Mol Biol. 2021;2320:135-149. (PMID: 34302655)
Stem Cell Reports. 2017 Nov 14;9(5):1546-1559. (PMID: 29107590)
Nat Commun. 2021 Aug 26;12(1):5142. (PMID: 34446706)
Regen Ther. 2023 Sep 22;24:479-488. (PMID: 37767182)
Int J Cardiol. 2017 Aug 15;241:379-386. (PMID: 28377185)
Curr Cardiol Rep. 2023 Jun;25(6):505-514. (PMID: 37129759)
Front Bioeng Biotechnol. 2023 Mar 22;11:1155052. (PMID: 37034258)
ACS Omega. 2020 Sep 15;5(38):24340-24350. (PMID: 33015450)
Front Cell Dev Biol. 2022 Apr 01;10:864516. (PMID: 35433671)
Heart Fail Rev. 2021 Sep;26(5):1231-1248. (PMID: 32306220)
Circ Res. 2020 Apr 10;126(8):1086-1106. (PMID: 32271675)
Biomed Mater. 2023 Mar 07;18(3):. (PMID: 36758240)
Am J Physiol Cell Physiol. 2010 Dec;299(6):C1234-49. (PMID: 20844252)
Circulation. 2021 May 18;143(20):1991-2006. (PMID: 33648345)
Acta Biomater. 2017 Jan 15;48:20-40. (PMID: 27826001)
Sci Rep. 2020 Aug 11;10(1):13575. (PMID: 32782331)
Curr Opin Genet Dev. 2021 Oct;70:54-60. (PMID: 34130066)
Circ Res. 2017 Dec 8;121(12):1323-1330. (PMID: 28974554)
J Biol Eng. 2019 Nov 11;13:83. (PMID: 31737091)
Pharmacol Ther. 2018 Mar;183:127-136. (PMID: 28986101)
ACS Appl Mater Interfaces. 2020 Oct 14;12(41):45673-45701. (PMID: 32937068)
Stem Cells. 2013 Mar;31(3):447-57. (PMID: 23193013)
Nat Protoc. 2013 Jan;8(1):162-75. (PMID: 23257984)
Adv Healthc Mater. 2020 Nov;9(22):e2001175. (PMID: 33000909)
ACS Appl Mater Interfaces. 2023 Apr 12;15(14):17518-17531. (PMID: 36992621)
Bioengineering (Basel). 2023 Jun 09;10(6):. (PMID: 37370633)
Adv Healthc Mater. 2023 Jul;12(19):e2300607. (PMID: 36975154)
Front Cell Dev Biol. 2017 May 05;5:50. (PMID: 28529939)
Biomaterials. 2015 Oct;67:52-64. (PMID: 26204225)
Stem Cell Res Ther. 2019 Mar 12;10(1):87. (PMID: 30867069)
Cardiovasc Res. 2023 Mar 17;119(1):167-182. (PMID: 35394010)
Stem Cell Res Ther. 2022 Jul 23;13(1):332. (PMID: 35870954)
Int J Biol Macromol. 2021 Jun 1;180:590-598. (PMID: 33711373)
Front Bioeng Biotechnol. 2023 Feb 08;11:1094397. (PMID: 36845196)
Mater Horiz. 2021 Feb 1;8(2):426-446. (PMID: 34821263)
Biomed Mater. 2018 Aug 06;13(5):055014. (PMID: 30026407)

SONATA BIS 9 Program No. 2019/34/E/ST5/00381 Narodowe Centrum Nauki

0 (Polyurethanes)
0 (Polyesters)
24980-41-4 (polycaprolactone)

Date Created: 20240605 Date Completed: 20240605 Latest Revision: 20240608

20240608

PMC11153585

10.1038/s41598-024-63905-z

38839879